Aimmune Reverses Gains as Street Weighs Peanut Drug’s Potential

(Bloomberg) -- A positive recommendation from a group of advisers to the U.S. Food and Drug Administration in favor of Aimmune Therapeutics Inc.’s Palforzia indicates the peanut allergy drug will w...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.